image: Fahad Al-Jalajel, Saudi Minister of Health, led a political and corporate delegation to visit BGI Genomics.
Credit: BGI Genomics
On December 1st, His Excellency Fahad Al-Jalajel, Saudi Minister of Health, led a political and corporate delegation to visit BGI Genomics. This marked the first stop of his inaugural visit to China since taking office. The delegation was jointly welcomed by Yin Ye, CEO of BGI Group; Zhao Lijian, CEO of BGI Genomics; Du Yutao, COO of BGI Genomics, Li Ning, deputy general manager of BGI Genomics, Xiong Tao, International VP of BGI Genomics; and Ma Zhe, General Manager of BGI Genomics West Asia.
During the visit, the two parties exchanged views on the latest progress and prospects for cooperation in the fields of genomics and precision medicine. The Saudi delegation learned in detail about BGI Genomics' achievements in global health and biotechnology innovation, and affirmed its contribution to the prevention and control of the epidemic in Saudi Arabia during the COVID-19 pandemic. The delegation acknowledged BGI Genomics’ significant role in advancing global public health development.
After the meeting, Zhao Lijian and Ma Zhe, signed a Memorandum of Understanding (MOU) on behalf of BGI Genomics with Eng. Fahad bin Mohammed AlShebel, CEO of NUPCO, and Mr. Fahad Abdullah Saad Al-Farraj, Executive Vice President of AL-DAWAA, respectively. The signing was witnessed by Fahad Al-Jalajel and Yin Ye.
The visit and signing of MOUs further solidify the strategic collaborations between BGI Genomics and partners in Saudi Arabia, marking a new milestone in cooperation between China and Saudi Arabia in the fields of public health and biotechnology. It also underscores BGI Genomics' leadership in the global biotechnology sector. Looking ahead, BGI Genomics remains committed to localized innovation and collaboration, working with partners to advance the application of genomics technology in Saudi Arabia and contribute to achieving the health goals outlined in Saudi Arabia's Vision 2030.
About BGI Genomics
BGI Genomics, headquartered in Shenzhen, China, is the world's leading integrated solutions provider of precision medicine. Its services cover more than 100 countries and regions and involve more than 2,300 medical institutions. In July 2017, as a subsidiary of BGI Group, BGI Genomics (300676.SZ) officially began trading on the Shenzhen Stock Exchange.